NCT00296855 - Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease | Biotech Hunter

Enrollment

261

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

February 28, 2007

Conditions

Peripheral Vascular Diseases

Interventions

DRUG

Vasovist (BAY86-5283, MS-325)

All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL

Trial Locations (26)

1021

Vienna

1090

Vienna

3100

Sankt Pölten

4031

Basel

5404

Baden

8036

Graz

10700

México D.F.

13353

Berlin

20251

Hamburg

22649

Rio de Janeiro

45147

Essen

48149

Münster

50931

Cologne

53105

Bonn

55131

Mainz

60389

Frankfurt am Main

60596

Frankfurt am Main

64460

Monterrey

Unknown

Buenos Aires

B1832BQS

Lornas de Zamora

C1082ACA

Buenos Aires

C1428DDO

Buenos Aires

80060-900

Curitiba

01323-001

São Paulo

05403-900

São Paulo

06760

Mexico D. F.